Search - tctmd.com

Displaying 241 - 260 of 731

Sort: Relevancy | Date

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

November 10, 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

November 05, 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

Renal Function Affects Ticagrelor/Aspirin Impact on Recurrent Stroke: CHANCE-2

News Daily News

Renal Function Affects Ticagrelor/Aspirin Impact on Recurrent Stroke: CHANCE-2

Yael L. Maxwell

November 03, 2022

November 2022 News Roundup

News Opinion CV Team Dispatch

November 2022 News Roundup

November 01, 2022

COVID Vaccine Thrombosis, Thrombocytopenia Risks Clarified in International Study

News Daily News

COVID Vaccine Thrombosis, Thrombocytopenia Risks Clarified in International Study

October 28, 2022

New Biomarker-Based Risk Score Performs Well in ACS

News Daily News

New Biomarker-Based Risk Score Performs Well in ACS

Michael O'Riordan

October 25, 2022

Too Few Veterans Get Intensified Lipid-Lowering Therapy After Coronary Events

News Daily News

Too Few Veterans Get Intensified Lipid-Lowering Therapy After Coronary Events

Yael L. Maxwell

October 24, 2022

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

October 05, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

October 2022 News Roundup

News Opinion CV Team Dispatch

October 2022 News Roundup

October 01, 2022

Initiative Lowers Unnecessary Aspirin Use in Warfarin Users

News Daily News

Initiative Lowers Unnecessary Aspirin Use in Warfarin Users

September 26, 2022

mRNA Vaccine-Linked Myocarditis Resolves in Time, Without Clinical Events

News Daily News

mRNA Vaccine-Linked Myocarditis Resolves in Time, Without Clinical Events

Michael O'Riordan

September 26, 2022

Most Patient-Reported Outcome Measures in CVD Fall Short

News Daily News

Most Patient-Reported Outcome Measures in CVD Fall Short

September 23, 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

September 01, 2022

Large RCTs of High-Dose Flu Vaccines Doable, DANFLU-1 Confirms

News Conference News ESC 2022

Large RCTs of High-Dose Flu Vaccines Doable, DANFLU-1 Confirms

Yael L. Maxwell

August 31, 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.